Intangible Assets

6 Months Ended

Jun. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 5 – Intangible Assets

Intangible assets as of June 30, 2018 and December 31, 2017 consists of the following:

	Useful Life	Gross Carrying Cost		Accumulated Amortization			Impairment Loss		Net Book Value
June 30, 2018
DermaWand® Purchase	5 years	$	1,163,816	$	(727,451	)	$	-	$	436,365
PhotoMedex Patented/Unpatented Technology	5 years		940,628		(266,509	)		-		674,119
PhotoMedex Trademarks	5 years		1,100,000		(311,667	)		-		788,333
Total		$	3,204,444	$	(1,305,627	)	$	-	$	1,898,817

	Useful Life	Gross Carrying Cost		Accumulated Amortization			Impairment Loss			Net Book Value
December 31, 2017
Ermis Labs Formulations/  Trademarks	5 years	$	1,512,443	$	(277,281	)	$	(1,235,162	)	$	-
DermaWand® Purchase	5 years		1,163,816		(581,673	)		-			582,143
PhotoMedex Patented/Unpatented Technology	5 years		940,628		(172,447	)		-			768,181
PhotoMedex Trademarks	5 years		1,100,000		(201,667	)		-			893,333
Total		$	4,716,887	$	(1,233,068	)	$	(1,235,162	)	$	2,248,657

Amortization expense was approximately $177,000 and $354,000 and $251,000 and $442,000 for the three and six months ended June 30, 2018 and 2017, respectively, of which approximately $75,000 of amortization expense is included in cost of sales for each of the three and six months ended June 30, 2018 and 2017, and approximately $102,000 and $204,000 is included in general and administrative expenses for the three and six months ended June 30, 2018, and $116,000 and $292,000 is included in general and administrative expenses for the three and six months ended June 30, 2017, respectively. Management evaluates the intangible assets for impairment when there is a triggering event.

The following table outlines the estimated future amortization expense related to the intangible assets held as of June 30, 2018:

2018 (remaining six months)	$	359,000
2019		690,000
2020		408,000
2021		408,000
2022		34,000
Total	$	1,899,000